Atossa Genetics Promising News for Endoxifen
Atossa Genetics (ATOS) has promising news from a Phase 2 trial of its topical Endoxifen for mammographic breast density (MBD) reduction.
Preliminary analysis from a recently completed Phase 2 study of Atossa’s proprietary 20mg daily topical Endoxifen has caused a significant and a rapid reduction . . .
This content is for paid subscribers.
Today’s Highlights
June 27, 2019
